Reneo Pharmaceuticals(RPHM) - 2025 Q3 - Quarterly Results

Exhibit 99.1 OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the ...